Both in Biotechnology
Tarsus Pharmaceuticals vs Denali Therapeutics
Over the past year TARS returned +32.0% and DNLI returned +43.3%; their daily moves had a correlation of 0.32.
TARS +32.0% DNLI +43.3%Growth of $1, one year, split-adjusted
| Metric | TARS | DNLI |
|---|---|---|
| Price | $76.69 | $20.81 |
| Market cap | $3.59B | $3.33B |
| Today | −0.16% | −0.81% |
| 1 month | +6.9% | −13.3% |
| 6 months | +14.6% | +15.1% |
| Year to date | −6.3% | +26.0% |
| 1 year | +36.2% | +49.2% |
| Revenue growth (YoY) | +69.4% | — |
| Gross margin | 93.0% | 97.4% |
| Net margin | −10.7% | −3539.2% |
| P/E (TTM) | — | — |
| Price / sales | 5.9× | 923.0× |
| Net cash | $376.9M | $705.0M |
| Dividend yield | — | — |
| Volatility (60d) | 54.0% | 50.0% |
| Short % of float | 16.2% | 12.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).